Veracyte
The Principal Bioinformatics Scientist will lead the bioinformatics strategy, design, and development of next-generation minimal residual disease (MRD) laboratory-developed tests, overseeing assay concepts, analytical development, and validation while collaborating with wet‑lab, clinical, quality, regulatory, and software teams. This senior technical leader will own the bioinformatics pipeline from concept through launch, ensuring compliance with regulated quality systems.
Headquarters
South San Francisco, California, United States
Company Size
501-1000 employees
Founded
2008
Veracyte is a genomic diagnostics company that develops and delivers molecular tests to provide clinicians with actionable molecular insights for cancer care. Their high‑performing tests support patient management across thyroid, prostate, bladder, breast, and lung cancers, helping physicians give patients informed answers now and tailor personalized treatment plans. Veracyte focuses on translating genomic data into clinically useful results to improve diagnostic accuracy and guide therapy decisions. Their mission—"Exceptional cancer care begins with exceptional diagnostics"—reflects a commitment to advancing precision oncology and better patient outcomes.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Veracyte.
24% above the average for this role
Veracyte to Participate in Upcoming Investor Conferences
3 weeks ago